NasdaqCM:HSGX

Stock Analysis Report

Executive Summary

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Histogenics has significant price volatility in the past 3 months.
  • Histogenics is not covered by any analysts.

Share Price & News

How has Histogenics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.2%

NasdaqCM:HSGX

0.5%

US Biotechs

-0.7%

US Market


1 Year Return

-92.8%

NasdaqCM:HSGX

-8.0%

US Biotechs

-0.5%

US Market

HSGX underperformed the Biotechs industry which returned -8.1% over the past year.

HSGX underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

HSGXIndustryMarket
7 Day-4.2%0.5%-0.7%
30 Day-6.5%1.0%-3.0%
90 Day5.5%3.2%0.9%
1 Year-92.8%-92.8%-7.3%-8.0%1.7%-0.5%
3 Year-93.5%-93.5%9.3%5.6%39.5%30.4%
5 Yearn/a7.7%2.7%54.1%37.0%

Price Volatility Vs. Market

How volatile is Histogenics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Histogenics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Histogenics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Histogenics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Histogenics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Histogenics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Histogenics performed over the past 5 years?

28.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Histogenics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Histogenics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Histogenics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Histogenics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Histogenics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Histogenics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Histogenics's financial position?


Financial Position Analysis

Histogenics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Histogenics's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Histogenics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Histogenics's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Histogenics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Histogenics has less than a year of cash runway based on current free cash flow.

Histogenics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.2% each year.


Next Steps

Dividend

What is Histogenics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Histogenics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Histogenics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Histogenics has not reported any payouts.

Unable to verify if Histogenics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Histogenics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Histogenics's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average board tenure


CEO

Histogenics has no CEO, or we have no data on them.


Board Age and Tenure

1.2yrs

Average Tenure

53.5yo

Average Age

The average tenure for the Histogenics board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$158,77215 Jan 19
Intrexon Corporation
EntityCompany
Shares998,204
Max PriceUS$0.17
SellUS$271,05903 Jan 19
Split Rock Partners, LLC
EntityCompany
Shares2,775,538
Max PriceUS$0.11

Ownership Breakdown


Management Team

  • Jonathan Lieber (49yo)

    Interim Chief Financial Officer

    • Tenure: 4.1yrs
    • Compensation: US$555.85k

Board Members

  • Josh Baltzell (50yo)

    Chairman of the Board

    • Tenure: 0.5yrs
    • Compensation: US$71.91k
  • Charlie Cooney (75yo)

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Kyriacos Athanasiou

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Jennifer Elisseeff

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Lawrence Bonassar

    Member of Scientific Advisory Board

    • Tenure: 2.8yrs
  • R. Smith

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Lonnie Shea

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Shuichi Mizuno

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Gloria Matthews (49yo)

    Chairperson of Clinical Advisory Board

    • Tenure: 1.9yrs
    • Compensation: US$538.64k
  • David Hood (57yo)

    Director

    • Tenure: 0.1yrs

Company Information

Histogenics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Histogenics Corporation
  • Ticker: HSGX
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$17.681m
  • Shares outstanding: 94.60m
  • Website: https://www.histogenics.com

Number of Employees


Location

  • Histogenics Corporation
  • 830 Winter Street
  • 3rd Floor
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HSGXNasdaqCM (Nasdaq Capital Market)YesClass A Common StockUSUSDDec 2014

Biography

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 00:51
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.